Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ATNX Stock Summary
In the News
Why Is Athenex (ATNX) Stock Down 54% Today?
Athenex (NASDAQ: ATNX ) stock is falling on Monday after the company announced an agreement with lenders to pursue an expedited sales process. According to a press release from the company, this agreement has it expecting to complete the process by July 1, 2023.
Athenex (ATNX) Upgraded to Buy: Here's Why
Athenex (ATNX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
A Short Guide to Making Money With Penny Stocks in 2023
Use these tips for making money with penny stocks The post A Short Guide to Making Money With Penny Stocks in 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Penny Stocks To Buy? 3 Stocks Under $1 To Watch Now
Penny stocks under $1 to watch this month. The post Penny Stocks To Buy?
Best Penny Stocks To Buy? 10 Under $1 To Watch This Week
Penny stocks to buy for under $1 but are they worth the risk? The post Best Penny Stocks To Buy?
Best Penny Stocks To Buy? 6 Under $1 To Watch Now
Penny stocks under $1 to watch right now. The post Best Penny Stocks To Buy?
3 Hot Penny Stocks Under $1 To Watch This Week
Penny stocks under $1 to watch this week. The post 3 Hot Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
3 Tips for Identifying Penny Stocks With High Potential
Use these tips for finding penny stocks to buy in 2022 The post 3 Tips for Identifying Penny Stocks With High Potential appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Is Athenex (ATNX) Stock Up 44% Today?
Athenex (NASDAQ: ATNX ) stock is rocketing higher on Tuesday thanks to positive results from a high-risk early-stage breast cancer clinical trial. The Phase 2 study covers the use of the company's oral paclitaxel plus encequidar in combination with a PD-1 inhibitor and carboplatin.
Athenex, Inc. (ATNX) CEO Johnson Lau on Q3 2022 Results - Earnings Call Transcript
Athenex, Inc. (NASDAQ:ATNX ) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Tim McCarthy - MD, Investor Relations Johnson Lau - Chief Executive Officer Dan Lang - President, Athenex Cell Therapy Darrel Cohen - Chief Medical Officer, Cell Therapy Jeff Yordon - Chief Operating Officer Joe Annoni - Chief Financial Officer Conference Call Participants Jon Miller - Evercore Yale Jen - Laidlaw & Co Operator Good day, ladies and gentlemen and welcome to the Athenex Third Quarter 2022 Earnings Conference Call. [Operator Instructions] I would now like to hand the conference over to Tim McCarthy, Managing Director of Investor Relations at LifeSci Advisors.
ATNX Financial details
ATNX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 27.62 | 27.34 | 33.94 | 23.13 | 15.72 | |
Net income per share | -36.4 | -33.9 | -34.89 | -37.39 | -15.13 | |
Operating cash flow per share | -33.9 | -26.32 | -30.85 | -27.4 | -11.47 | |
Free cash flow per share | -34.97 | -31.11 | -34.02 | -29.42 | -11.78 | |
Cash per share | 33.3 | 43.43 | 52.82 | 11.91 | 5.61 | |
Book value per share | 43.19 | 50.83 | 42.26 | -175.83 | -0.99 | |
Tangible book value per share | 24.93 | -12.7 | -11.54 | -17.04 | -11.02 | |
Share holders equity per share | 43.19 | 50.83 | 42.26 | -175.83 | -0.99 | |
Interest debt per share | 15.05 | 19.13 | 39.81 | 42.5 | 10.43 | |
Market cap | 818.85M | 1.13B | 941.02M | 141.36M | 19.3M | |
Enterprise value | 815.82M | 1.07B | 1.01B | 239.99M | 26.03M | |
P/E ratio | -6.97 | -9.01 | -6.34 | -0.73 | -0.19 | |
Price to sales ratio | 9.19 | 11.17 | 6.52 | 1.18 | 0.19 | |
POCF ratio | -7.49 | -11.6 | -7.17 | -0.99 | -0.26 | |
PFCF ratio | -7.26 | -9.82 | -6.5 | -0.92 | -0.25 | |
P/B Ratio | 5.88 | 6.01 | 5.23 | -0.15 | -2.97 | |
PTB ratio | 5.88 | 6.01 | 5.23 | -0.15 | -2.97 | |
EV to sales | 9.16 | 10.54 | 7.02 | 2 | 0.25 | |
Enterprise value over EBITDA | -7.27 | -9.07 | -8.25 | -2.09 | -0.37 | |
EV to operating cash flow | -7.46 | -10.95 | -7.72 | -1.69 | -0.35 | |
EV to free cash flow | -7.23 | -9.26 | -7 | -1.57 | -0.34 | |
Earnings yield | -0.14 | -0.11 | -0.16 | -1.37 | -5.13 | |
Free cash flow yield | -0.14 | -0.1 | -0.15 | -1.08 | -3.99 | |
Debt to equity | 0.34 | 0.34 | 0.88 | -0.22 | -6.51 | |
Debt to assets | 0.2 | 0.21 | 0.41 | 0.75 | 0.21 | |
Net debt to EBITDA | 0.03 | 0.54 | -0.59 | -0.86 | -0.1 | |
Current ratio | 3.31 | 3.23 | 4.7 | 0.64 | 1.09 | |
Interest coverage | -70.73 | -17.19 | -11.03 | -5.54 | -2.71 | |
Income quality | 0.85 | 0.78 | 0.88 | 0.73 | 0.76 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 1.35 | 0.83 | 0.53 | 0.67 | 0.5 | |
Intangibles to total assets | 0.21 | 0.15 | 0.13 | 0.27 | 0.35 | |
Capex to operating cash flow | 0.03 | 0.18 | 0.1 | 0.07 | 0.03 | |
Capex to revenue | -0.04 | -0.18 | -0.09 | -0.09 | -0.02 | |
Capex to depreciation | -1.05 | -4.65 | -3 | -2.25 | -0.89 | |
Stock based compensation to revenue | 0.12 | 0.1 | 0.08 | 0.08 | 0.06 | |
Graham number | 188.08 | 196.92 | 182.14 | 384.6 | 18.4 | |
ROIC | -0.68 | -0.46 | -0.37 | 0.15 | -1.71 | |
Return on tangible assets | -0.64 | -0.48 | -0.44 | -0.99 | -0.75 | |
Graham Net | 9.05 | -32.49 | -29.97 | -35.58 | -19.13 | |
Working capital | 119.14M | 159.4M | 229.82M | -34.14M | 10.05M | |
Tangible asset value | 80.43M | -47.04M | -49.11M | -88.58M | -72.11M | |
Net current asset value | 68.49M | -79.01M | -92.37M | -222.22M | -79.13M | |
Invested capital | 0.34 | 0.34 | 0.88 | -0.22 | -6.51 | |
Average receivables | 10.71M | 14.82M | 20.15M | 25.12M | 27.25M | |
Average payables | 14.83M | 18.16M | 21M | 17.71M | 25.21M | |
Average inventory | 22.67M | 30.71M | 30.74M | 31.77M | 38.67M | |
Days sales outstanding | 53.05 | 60.18 | 59.67 | 80.9 | 98.92 | |
Days payables outstanding | 100.92 | 122.32 | 71.48 | 74.16 | 161.51 | |
Days of inventory on hand | 223.53 | 171.07 | 110.42 | 153.63 | 204.53 | |
Receivables turnover | 6.88 | 6.07 | 6.12 | 4.51 | 3.69 | |
Payables turnover | 3.62 | 2.98 | 5.11 | 4.92 | 2.26 | |
Inventory turnover | 1.63 | 2.13 | 3.31 | 2.38 | 1.78 | |
ROE | -0.84 | -0.67 | -0.83 | 0.21 | 15.21 | |
Capex per share | -1.06 | -4.79 | -3.17 | -2.03 | -0.31 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q4
Metric | History | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 4.56 | 5.38 | 5.58 | 4.81 | 3.14 | |
Net income per share | -17.8 | -5.51 | -4.25 | -2.81 | -3.6 | |
Operating cash flow per share | -7.02 | -4.32 | -3.62 | -2.33 | -1.8 | |
Free cash flow per share | -5.41 | -4.36 | -3.77 | -2.49 | -1.8 | |
Cash per share | 8.3 | 6.78 | 6.58 | 5.19 | 4.6 | |
Book value per share | 9.35 | 6.88 | 2.11 | 3.56 | -0.82 | |
Tangible book value per share | -3.8 | -9.19 | -15.91 | -9.31 | -9.04 | |
Share holders equity per share | 9.35 | 6.88 | 2.11 | 3.56 | -0.82 | |
Interest debt per share | 29.76 | 25.02 | 14.52 | 7.01 | 6.65 | |
Market cap | 148.8M | 91.66M | 46.26M | 37.57M | 23.54M | |
Enterprise value | 271.34M | 198.17M | 88.05M | 45.02M | 30.28M | |
P/E ratio | -0.38 | -0.75 | -0.48 | -0.48 | -0.2 | |
Price to sales ratio | 5.97 | 3.08 | 1.47 | 1.12 | 0.94 | |
POCF ratio | -3.87 | -3.84 | -2.26 | -2.31 | -1.64 | |
PFCF ratio | -5.02 | -3.81 | -2.17 | -2.16 | -1.64 | |
P/B Ratio | 2.91 | 2.41 | 3.88 | 1.51 | -3.62 | |
PTB ratio | 2.91 | 2.41 | 3.88 | 1.51 | -3.62 | |
EV to sales | 10.88 | 6.67 | 2.79 | 1.34 | 1.21 | |
Enterprise value over EBITDA | -2.76 | -9.2 | -4.04 | -3.75 | -1.83 | |
EV to operating cash flow | -7.06 | -8.3 | -4.3 | -2.77 | -2.1 | |
EV to free cash flow | -9.16 | -8.23 | -4.13 | -2.59 | -2.11 | |
Earnings yield | -0.65 | -0.33 | -0.52 | -0.52 | -1.22 | |
Free cash flow yield | -0.2 | -0.26 | -0.46 | -0.46 | -0.61 | |
Debt to equity | 3.09 | 3.52 | 6.51 | 1.72 | -6.51 | |
Debt to assets | 0.56 | 0.56 | 0.35 | 0.19 | 0.21 | |
Net debt to EBITDA | -1.25 | -4.94 | -1.92 | -0.62 | -0.41 | |
Current ratio | 1.39 | 1.63 | 0.41 | 1.49 | 1.09 | |
Interest coverage | -19.67 | -4.98 | -5.07 | -2.05 | -1.55 | |
Income quality | 0.39 | 0.78 | 0.9 | 0.82 | 0.56 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.73 | 0.47 | 0.42 | 0.27 | 0.65 | |
Intangibles to total assets | 0.25 | 0.3 | 0.33 | 0.32 | 0.35 | |
Capex to operating cash flow | -0.23 | 0.01 | 0.04 | 0.07 | 0 | |
Capex to revenue | 0.35 | -0.01 | -0.03 | -0.03 | 0 | |
Capex to depreciation | 8.68 | -0.22 | -1.4 | -1.46 | 0.53 | |
Stock based compensation to revenue | 0.08 | 0.06 | 0.05 | 0.04 | 0.06 | |
Graham number | 61.17 | 29.21 | 14.22 | 15.02 | 8.13 | |
ROIC | -0.46 | -0.13 | -0.23 | -0.18 | -0.4 | |
Return on tangible assets | -0.46 | -0.18 | -0.16 | -0.13 | -0.22 | |
Graham Net | -27.47 | -24.57 | -27.94 | -19.96 | -15.68 | |
Working capital | 37.35M | 50.8M | -53.02M | 41.8M | 10.05M | |
Tangible asset value | -20.77M | -50.77M | -89.88M | -64.93M | -72.11M | |
Net current asset value | -99.6M | -84.48M | -202.14M | -94.41M | -79.13M | |
Invested capital | 3.09 | 3.52 | 6.51 | 1.72 | -6.51 | |
Average receivables | 30.2M | 28.12M | 31.71M | 33.37M | 30.39M | |
Average payables | 19.81M | 16.67M | 19M | 23.23M | 29.38M | |
Average inventory | 33.13M | 37.97M | 39.55M | 39.95M | 42.35M | |
Days sales outstanding | 96.14 | 89.64 | 96.59 | 88.34 | 100.06 | |
Days payables outstanding | 72.81 | 64.15 | 83.39 | 81.35 | 166.7 | |
Days of inventory on hand | 150.85 | 159.38 | 147.52 | 136.41 | 211.1 | |
Receivables turnover | 0.94 | 1 | 0.93 | 1.02 | 0.9 | |
Payables turnover | 1.24 | 1.4 | 1.08 | 1.11 | 0.54 | |
Inventory turnover | 0.6 | 0.56 | 0.61 | 0.66 | 0.43 | |
ROE | -1.9 | -0.8 | -2.01 | -0.79 | 4.42 | |
Capex per share | 1.61 | -0.03 | -0.15 | -0.16 | 0.01 |
ATNX Frequently Asked Questions
What is Athenex, Inc. stock symbol ?
Athenex, Inc. is a US stock , located in Buffalo of Ny and trading under the symbol ATNX
What is Athenex, Inc. stock quote today ?
Athenex, Inc. stock price is $- today.
Is Athenex, Inc. stock public?
Yes, Athenex, Inc. is a publicly traded company.